- Oops!Something went wrong.Please try again later.
Shares of Bausch Health Cos (NYSE:BHC) decreased 0.3% in pre-market trading after the company reported Q4 results.
Earnings per share increased 18.75% year over year to $1.33, which beat the estimate of $1.12.
Revenue of $2,213,000,000 declined by 0.49% year over year, which beat the estimate of $2,170,000,000.
The upcoming fiscal year's revenue expected to be between $8,600,000,000 and $8,800,000,000.
Details Of The Call
Date: Feb 24, 2021
Time: 08:00 AM
Recent Stock Performance
Company's 52-week high was at $32.50
52-week low: $11.15
Price action over last quarter: Up 87.39%
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-U.S. markets. Bausch is the market leader in consumer visioncare in India and China, and the fourth- largest visioncare company by sales in the United States.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.